![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, July 10, 2014 10:54:26 AM
"As to the public interest, Antares avers that its product is available and in use for the same indications as Medac's product, i.e., rheumatoid arthritis and psoriasis. Medac responds that the products are not interchangeable as RASUVO provides additional dosing flexibility not offered through OTREXUP. AS OVER 90% OF PRESCRIBED DOSES ARE FOR THE STANDARD DOSES THAT ANTARES ALREADY SELLS, THIS FACTOR IS NEUTRAL." (I put the last sentence in all caps for the emphasis and to draw attention to this Court statement)
So, OTREXUP addresses the already 90% standard dosing of mtx available today, does RASUVO's potential market niche only cover the remaining 10%??
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM